Advanced Search

Technical Analysis for KALA - Kala Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 7.47 -1.84% -0.14
KALA closed down 1.84 percent on Friday, April 16, 2021, on 47 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
6 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical KALA trend table...
Date Alert Name Type % Chg
Stochastic Reached Overbought Strength 0.00%
Weak + Overbought Other 0.00%
Overbought Stochastic Strength 0.00%
Crossed Above 20 DMA Bullish -1.84%
Gapped Up Strength -1.84%
Up 3 Days in a Row Strength -1.84%
20 DMA Resistance Bearish 3.61%
Fell Below 20 DMA Bearish 8.73%
Crossed Above 20 DMA Bullish -1.32%
Up 3 Days in a Row Strength -1.32%
Older End-of-Day Signals for KALA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% 1 day ago
Fell Below Previous Day's Low 1 day ago
Down 2 % 1 day ago
Down 1% 1 day ago
Rose Above 20 DMA 3 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators Basic chart:

Profile

Kala Pharmaceuticals Inc. is a United States-based company that is developing ophthalmic treatments based on the Company’s Mucosal Penetrating Product (MPP) platform. The Company’s topical ocular MPP formulations enhance penetration of diverse therapeutic agents into ocular tissue, including those in the back of the eye, by facilitating penetration through the mucus layer of tear film. Its product development pipeline includes a 1% formulation of loteprednol etabonate to treat post-surgical ocular inflammation and pain; a 0.25% LE-MPP formulation for dry eye, blepharitis, and retinal disease, and a topically applied receptor tyrosine kinase inhibitir (RTKi-MPP) for the treatment of wet age-related macular degeneration (AMD).
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Eye Pain Organ Systems Inflammation Ophthalmic Macular Degeneration Related Macular Degeneration Retina Tyrosine Kinase Wet Age Related Macular Degeneration Glucocorticoids Retinal Disease Receptor Tyrosine Kinase Blepharitis Post Surgical Ocular Inflammation

Is KALA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Apr 14 JPMorgan: 2 Stocks for Stellar Long-Term Gains
Mar 17 Kala Pharmaceuticals (KALA) Presents At Oppenheimer 31st Annual Healthcare Conference - Slideshow
Mar 16 Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna
Mar 9 How Much Are Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Insiders Spending On Buying Shares?
Mar 2 Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March
Feb 25 Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2020 Results - Earnings Call Transcript
Feb 25 Kala Pharmaceuticals EPS misses by $0.09, misses on revenue
Feb 25 Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Feb 20 The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings
Feb 18 Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call
See more KALA news...

Indicators

Indicator Value
52 Week High 14.68
52 Week Low 6.0
Average Volume 2,319,554
200-Day Moving Average 8.14
50-Day Moving Average 7.84
20-Day Moving Average 7.22
10-Day Moving Average 7.27
Average True Range 0.49
ADX 13.08
+DI 25.73
-DI 21.75
Chandelier Exit (Long, 3 ATRs ) 6.86
Chandelier Exit (Short, 3 ATRs ) 7.48
Upper Bollinger Band 8.11
Lower Bollinger Band 6.32
Percent B (%b) 0.64
BandWidth 24.77
MACD Line -0.08
MACD Signal Line -0.16
MACD Histogram 0.0797
Fundamentals Value
Market Cap 418.88 Million
Num Shares 56.1 Million
EPS -2.87
Price-to-Earnings (P/E) Ratio -2.61
Price-to-Sales 64.50
Price-to-Book 3.86
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.00
Resistance 3 (R3) 7.99 7.82 7.91
Resistance 2 (R2) 7.82 7.68 7.82 7.88
Resistance 1 (R1) 7.64 7.60 7.56 7.65 7.85
Pivot Point 7.47 7.47 7.42 7.47 7.47
Support 1 (S1) 7.29 7.33 7.21 7.30 7.09
Support 2 (S2) 7.12 7.25 7.12 7.06
Support 3 (S3) 6.94 7.12 7.03
Support 4 (S4) 6.95